Company Profile
Recce Pharmaceuticals Ltd, discovers develops, and commercializes synthetic antiยinfectives in Australia, the United Kingdom, and the United States. The company's lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections.
In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis R327 Topical Gel, which is Phase II clinical trial for the treatment of acute bacterial skin and skin structure infections is in Phase I/II clinical trials for topical wound infections and diabetic foot infections.
The company has strategic partnership with Murdoch Children's Research Institute for development of the Acinetobacter baumannii and Mycobacterium abscessus cooperative R&D agreement with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to be tested against highly hazardous pathogens. Incorporated in 2007 and headquartered in Sydney, Australia, Recce Pharmaceuticals was formerly known as Recce Limited before rebranding in November 2017.